Teladoc Health stock has shed half its value in the past six months. An analyst at Goldman Sachs says it's time to buy shares of the virtual-healthcare firm.
A significant number of ivermectin prescriptions come from a small minority of doctors who are willing to write them, often using telemedicine to do so. The same doctors frequently promote anti-vaccine conspiracy theories.
Using telehealth as a substitute for an in-person doctor visit comes with risks. If used incorrectly or negligently, it has enormous potential to lead to an injury or worsened patient condition and medical malpractice lawsuits for providers.
Anthem Blue Cross and Blue Shield in Connecticut has announced that its virtual primary care service is now available to some of its more than 1 million members in the state.
A day after Bank of America lowered its price target on Teladoc Health (TDOC -5.0%) by as much as a third, Piper Sandler has followed suit. Citing a bleak outlook for the company's Chronic Care Enrollments in Q1 2022, the analyst Sean Wieland lowered the per share target on the telehealth provider to $108 from $118 to indicate a premium of ~45% to the last close.
The new proposed Telehealth Extension and Evaluation Act asks for a "two-year extension of telehealth services following the COVID–19 emergency period" allowing medical practices to continue using video visits and be reimbursed for doing so until 2023.